Drugs /

therapeutic gamma delta t-lymphocytes

Back to Drugs List

Overview

NCI Definition [1]:
A subset of therapeutic autologous T-lymphocytes that express a T-cell receptor (TCR) composed of one gamma chain and one delta chain, with potential immunomodulating and antineoplastic activities. Upon administration of the therapeutic gamma delta T-lymphocytes, these cells secrete interferon-gamma (IFN-g), and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.

Clinical Trials

View Clinical Trials for therapeutic gamma delta t-lymphocytes

Therapeutic gamma delta t-lymphocytes has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating therapeutic gamma delta t-lymphocytes, 1 is phase 1 (1 open).

Acute myeloid leukemia is the most common disease being investigated in therapeutic gamma delta t-lymphocytes clinical trials [2].

Drug Details

Synonyms [2]:
γδ t cells, gd t cells, therapeutic gamma delta t lymphocytes, gammadelta t cells, gd t cells, gammadelta t cells
NCIT ID [1]:
C124644

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.